![David Armistead](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Dr. David Armistead is Entrepreneur-in-Residence at Third Rock Ventures LLC.
Prior to joining Thrid Rock ventures in 2010.
He was with Oxford Bioscience Partners.
He was Vice President and Site Head for the Amgen Cambridge Research Center, where he oversaw all aspects of the East Coast research activities for Amgen Inc. In 1997, he was a co-founder of Kinetix Pharmaceuticals, where he held the position of Vice President of Research and Development and Chief Scientific Officer until the acquisition of Kinetix by Amgen in December 2000.
Previously, he held the position of Head of Immunosuppressive Research and Development and Senior Scientist-Medicinal Chemistry at Vertex Pharmaceuticals.
Prior to that, he held the position of Senior Research Chemist in Inflammation and Immunology at Merck Sharp and Dohme Research Laboratories (Merck & Co., Inc.).
He left Merck to become a founding member of Vertex in 1989.
Dr. Armistead holds a Bachelor of Arts and a Master of Science in Chemistry from Virginia Polytechnic Institute, a Ph.D.
in Synthetic Chemistry from the University of South Carolina and was a National Institutes of Health Postdoctoral Fellow at Yale University.
Eerdere bekende functies van David Armistead
| Bedrijven | Functie | Einde |
|---|---|---|
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Private Equity Investor | 31-07-2010 |
| BLUEPRINT MEDICINES CORPORATION | Oprichter | - |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm focuses on the healthcare. It participates in early stage capital requirements. The firm also acts as lead investor. | Corporate Officer/Principal | - |
Gilead Connecticut, Inc.
 Gilead Connecticut, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals and biotechnology chemicals | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van David Armistead
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
16
Eerstegraads connecties
6
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
Oxford Bioscience Partners
Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Finance |
Virginia Polytechnic Institute & State University
 Virginia Polytechnic Institute & State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of South Carolina
 University of South Carolina Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gilead Connecticut, Inc.
Gilead Connecticut, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals and biotechnology chemicals | Health Technology |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm focuses on the healthcare. It participates in early stage capital requirements. The firm also acts as lead investor. | Finance |
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
Kies MarketScreener 
